KYTHERA Biopharmaceuticals News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

19.08.15	Cannabis On A High, PTN Jumps On Sprout News, TNXP At Ease, Watch APHB On Friday (RTTNews)
28.07.15	Allergan-KYTHERA Deal Gets U.S. Antitrust Approval (RTTNews)
17.06.15	Allergan To Buy Kythera Biopharma For $2.1 Bln (RTTNews)
17.06.15	So Long, KYTHERA (RTTNews)
17.06.15	Allergan To Acquire KYTHERA Biopharma For $75 Per KYTHERA Share - Quick Facts (RTTNews)
01.05.15	New Drug Approvals - The Month That Was (RTTNews)
30.04.15	FDA Approves Injection To Fight Double Chin (RTTNews)
30.04.15	KYTHERA Biopharma : FDA Okays Treatment For Fat Below Chin (RTTNews)
06.04.15	KYTHERA Grants 5 New Employees Stock Options Under Inducement Program (RTTNews)
10.03.15	ACRX Plunges On Zalviso News, CTIC Persists, HTBX On Fire, PIP Cuts Head Count (RTTNews)
10.03.15	FDA Panel Recommends Kythera Biopharma's Double-Chin Treatment (RTTNews)
05.02.15	DPLO To Dispense Breast Cancer Drug, New Use For Old Drugs Sought, CANF On Watch (RTTNews)
07.10.13	KYTHERA Commences Share Offering - Quick Facts (RTTNews)
04.10.13	Business Strategy, Partnerships, Presentation, and Appointment - Research Report on Merck, GSK, Sanofi, Intercept, and KYTHERA (PR Newswire)
20.09.13	Conference Call, Presentation of Drug Trial Results, Breakthrough Therapy Designation, Positive Results, and Drug Revival - Research Report on Johnson & Johnson, Lilly, GSK, Kythera, and Sanofi (PR Newswire)
17.09.13	Pre-market Movers For Sept 17 (MSFT, KYTH, DNDN, OUTR, ECTY) (RTTNews)
17.09.13	KYTH Gets A Facelift, PSTI To Resume Study, One Up, Two To Go For NBY (RTTNews)
16.09.13	KYTHERA Says REFINE-1 And REFINE-2 Trials Meet Primary, Secondary Endpoints (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V